Literature DB >> 8585744

Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells.

T Shirasaka1, S Chokekijchai, A Yamada, G Gosselin, J L Imbach, H Mitsuya.   

Abstract

We determined the anti-human immunodeficiency virus type 1 (anti-HIV-1) activities of various dideoxy-nucleoside analogs by using phytohemagglutinin-activated peripheral blood mononuclear cells (PHA-PBMs) and resting PBMs (R-PBMs) as target cells. The comparative order of anti-HIV-1 activity in PHA-PBMs was azidothymidine (AZT) > dideoxycytidine (ddC) > dideoxythymidinene (d4T) > dideoxyinosine (ddI) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) > 2'-beta-fluoro-dideoxyadenosine (F-ara-ddA), while that in R-PBMs was ddC > ddI, PMEA, and F-ara-ddA, >> AZT and d4T. A pronucleotide, bis-(S-acetylthioethanol)phosphotriester-ddAMP, which bypasses the anabolic monophosphorylation step for the intracellular delivery of ddAMP, was highly active both in PHA-PBMs and R-PBMs. These data may have basic and clinical relevance in the design of anti-HIV chemotherapy, particularly combination chemotherapy with dideoxynucleosides, and in the development of active pronucleotides.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8585744      PMCID： PMC162983          DOI： 10.1128/AAC.39.11.2555

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia.

Authors:  L S Lee; Y C Cheng
Journal:  J Biol Chem       Date:  1976-05-10       Impact factor: 5.157

2.  Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine.

Authors:  C Perigaud; A M Aubertin; S Benzaria; H Pelicano; J L Girardet; G Maury; G Gosselin; A Kirn; J L Imbach
Journal:  Biochem Pharmacol       Date:  1994-07-05       Impact factor: 5.858

3.  Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus.

Authors:  J Harel; E Rassart; P Jolicoeur
Journal:  Virology       Date:  1981-04-15       Impact factor: 3.616

4.  Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.

Authors:  M A Johnson; A Fridland
Journal:  Mol Pharmacol       Date:  1989-08       Impact factor: 4.436

5.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.

Authors:  S Kageyama; T Mimoto; Y Murakawa; M Nomizu; H Ford; T Shirasaka; S Gulnik; J Erickson; K Takada; H Hayashi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

Authors:  W Y Gao; R Agbaria; J S Driscoll; H Mitsuya
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

7.  Characterization of HIV isolates arising after prolonged zidovudine therapy.

Authors:  D L Mayers; F E McCutchan; E E Sanders-Buell; L I Merritt; S Dilworth; A K Fowler; C A Marks; N M Ruiz; D D Richman; C R Roberts
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

8.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

9.  Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.

Authors:  T Shirasaka; R Yarchoan; M C O'Brien; R N Husson; B D Anderson; E Kojima; T Shimada; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

10.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728
View more
  19 in total

1.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

2.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 3.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

4.  In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.

Authors:  M Tanaka; R V Srinivas; T Ueno; M F Kavlick; F K Hui; A Fridland; J S Driscoll; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 5.  Adefovir dipivoxil.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

6.  Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.

Authors:  A B van't Wout; L J Ran; M D de Jong; M Bakker; R van Leeuwen; D W Notermans; A E Loeliger; F de Wolf; S A Danner; P Reiss; C A Boucher; J M Lange; H Schuitemaker
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

7.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

Authors:  A M Caliendo; A Savara; D An; K DeVore; J C Kaplan; R T D'Aquila
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation.

Authors:  Bechan Sharma; Neerja Kaushik; Alok Upadhyay; Snehlata Tripathi; Kamalendra Singh; Virendra N Pandey
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

9.  Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.

Authors:  Jesús Saavedra-Lozano; Cynthia C McCoig; Yanying Cao; Ellen S Vitetta; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.

Authors:  Julie B Dumond; Y Sunila Reddy; Luigi Troiani; Jose F Rodriguez; Arlene S Bridges; Susan A Fiscus; Geoffrey J Yuen; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.